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ABSTRACT
Background: Whereas many patients respond quickly to
treatment with tumour necrosis factor (TNF) inhibitors,
some patients may experience significant but delayed
responses.
Objective: To evaluate the clinical response between 12
and 24 weeks in subjects with rheumatoid arthritis from
the Trial of Etanercept and Methotrexate with
Radiographic Patient Outcomes.
Methods: Clinical response was assessed at 24 weeks
in 12-week non-responders, according to American
College of Rheumatology (ACR) response criteria. The
proportion of subjects who successfully maintained
response to 52 weeks was analysed, as were radio-
graphic outcomes.
Results: Data from 682 subjects were included in the
analysis. Non and partial responders in all three groups
(etanercept, methotrexate and etanercept plus metho-
trexate) at week 12 showed an improvement in
responses at week 24. Over 80% of the week 24 ACR20/
50/70 responders in the etanercept plus methotrexate
arm sustained their response to 52 weeks. In the
etanercept arms, a delayed clinical response was not
associated with increased radiographic progression at
week 52.
Conclusion: A significant proportion of non and partial
responders to etanercept with or without methotrexate
therapy at week 12 achieved a good clinical response or
improved their overall clinical response at week 24.
Discontinuing TNF inhibitor therapy at 12 weeks may be
premature in some rheumatoid arthritis patients.
Tumour necrosis factor (TNF) inhibitors, particu-
larly in combination with methotrexate, have
demonstrated excellent symptomatic and radio-
graphic control in rheumatoid arthritis.
12A rapid
clinical response to such therapy, often within
2 weeks, is commonly observed.
134 It is widely
held that most patients who respond to TNF
inhibitor therapy will show an adequate response
after 12 weeks of treatment. Given the cost and
possible unnecessary exposure to an ineffective
medication, 12 weeks has been suggested as a
timepoint at which TNF inhibitor therapy should
be discontinued in non-responders. Discontinuing
therapy may be premature, however, if a propor-
tion of non-responders at 12 weeks become
responders at later timepoints.
56
In this analysis, we used data from the Trial of
Etanercept and Methotrexate with Radiographic
Patient Outcomes (TEMPO) to evaluate the extent
to which subjects not responding to TNF inhibitor
therapy at 12 weeks might respond at 24 weeks.
The long-term sustainability of the improvement
in response and radiographic outcome at week 52
was also assessed.
SUBJECTS AND METHODS
Subjects
Data from subjects treated with etanercept,
methotrexate and etanercept plus methotrexate
from the TEMPO study were used in this analysis.
1
Briefly, subjects had disease duration of between
6 months and 20 years, had active rheumatoid
arthritis defined as 10 or more swollen and 12 or
more painful joints and had at least one of the
following: erythrocyte sedimentation rate 28 mm/
h or greater; C-reactive protein 20 mg/l or greater;
or morning stiffness for 45 minutes or more.
Etanercept was given as 25 mg twice a week.
Patients randomly assigned to methotrexate arms
received 7.5 mg methotrexate once a week, which
was escalated to 20 mg once a week over 8 weeks.
Evaluations
American College of Rheumatology (ACR)20/50/
70 responses and Disease Activity Score using 28
joints (DAS28) were assessed at weeks 12, 24 and
52. Based on their clinical response at week 12,
subjects were categorised into ACR20 non-respon-
ders (no response at week 12), ACR50 non-
responders (ACR20 responders, but not ACR50
responders) and ACR70 non-responders (ACR50
responders, but not ACR70 responders).
Among the subjects who showed an improve-
ment in clinical response at week 24, the propor-
tion of subjects who successfully maintained the
improvement to at least 52 weeks was assessed.
The radiographic outcome at week 52 was eval-
uated using the mean change in total Sharp score
(TSS) and the percentage of non-progressors (TSS
change #0).
Frequencies and percentages were provided for
improvement and decrease in ACR response and
disease activity scores. One-way analysis of var-
iance was used to test the difference in DAS28
scores among groups (non-responder to non-
responder, non-responder to responder and respon-
der to responder). The paired-sample t test was
used to examine the difference in DAS28 scores
between week 12 and week 24 and for week 12
European League Against Rheumatism (EULAR)
non-responders who responded at week 24. Fisher’s
exact test was used to compare the difference in
radiographic progression between the week 12
responders and week 12 non-responders who
became responders at week 24 within each treat-
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comparisons. Logistic regression models were used to identify
predictors of response at 12 weeks. Results were considered
significant at p(0.05 two-sided. Non-responder imputation
was used to handle missing clinical and radiographic data. All
analyses were performed using the SAS STAT system version
9.1.
RESULTS
Baseline demographics
The TEMPO trial included 682 subjects (231 in the etanercept
plus methotrexate arm, 223 in the etanercept monotherapy arm
and 228 in the methotrexate monotherapy arm). Baseline
demographic characteristics for TEMPO subjects have been
described previously.
1 Briefly, the mean disease duration was
6.8 years, with 76% of subjects rheumatoid factor positive. The
mean age was 52.5 years and approximately three-quarters were
women. Subjects had a mean baseline DAS28 score of 6.8.
Improvement in ACR response
Results from the analysis of ACR20/50/70 responses at week 24
in week 12 non and partial responders are shown in fig 1. In the
etanercept plus methotrexate-treated subjects, 37.5% of week
12 ACR20 non-responders became ACR20 responders, 46.8% of
week 12 ACR50 non-responders became ACR50 responders and
51.1% of week 12 ACR70 non-responders became ACR70
responders. Similar improvements were also observed in the
monotherapy arms (23%–35% in the etanercept monotherapy
arm and 41%–45% in the methotrexate monotherapy arm).
Sustainability of ACR response
Of 21 ACR20, 37 ACR50 and 23 ACR70 responders at week 24
in the etanercept plus methotrexate arm, 17 (81.0%), 31 (83.8%)
and 19 (82.6%) subjects, respectively, showed a sustained
response at week 52 (fig 1). The sustainability of response
was more variable in the etanercept and methotrexate mono-
therapy arms, ranging from 67% to 89% and 50% to 63%,
respectively.
A decrease in ACR20/50/70 response was observed in some
subjects between weeks 12 and 24. In the etanercept plus
methotrexate arm, 18 out of 175 ACR20 responders (10.3%),
five out of 96 ACR50 responders (5.2%) and five out of 51
ACR70 responders (9.8%) decreased their response at week 24
(data not shown). Similarly, 11.5% of ACR20, 23.3% of ACR50
and 4.8% of ACR70 responders in the etanercept monotherapy
arm and 16.5% of ACR20, 10.2% of ACR50 and 23.1% of
ACR70 responders in the methotrexate monotherapy arm
decreased their response between weeks 12 and 24.
Improvement in DAS28 scores
In subjects from all three treatment arms who were EULAR
(moderate or good) non-responders at week 12, but became
responders at week 24, their mean DAS28 scores showed a
significant decrease from baseline to week 24 and from week 12
to week 24 (p,0.05) (fig 2). In the non-responder to non-
responder group, mean DAS28 scores at week 12 were similar to
those in the non-responder to responder group, arguing against
a ‘‘partial response’’ as the explanation for the later improve-
ment for those patients. Of note, mean DAS28 scores in the 12-
week non-responders/24-week responders improved signifi-
cantly at 24 weeks, but not to the same extent as for subjects
who achieved a response at 12 weeks.
Radiographic outcome at week 52
To determine if there was a slowing of radiographic progression
in subjects who were ACR20 non-responders at week 12, but
became responders at week 24 compared with week 12
Figure 1 Improvement and
sustainability of American College of
Rheumatology response.
ACR, American College of Rheumatology;
ETN, etanercept; MTX, methotrexate;
N, total of subgroup; NR, non-responder;
R, responder.
Table 1 Radiographic outcome at week 52 in week 12 and week 24 responders
N NP (%) p Value Mean TSS (95% CI)
ETN + MTX week 12 responder 171 69.0 0.440 20.53 (20.880 to 20.185)
ETN + MTX week 24 responder 20 80.0 21.35 (22.472 to 20.234)
ETN week 12 responder 145 59.3 0.177 20.23 (20.690 to 0.216)
ETN week 24 responder 24 75.0 20.19 (21.043 to 0.662)
MTX week 12 responder 133 48.1 0.037 0.64 (0.078 to 1.202)
MTX week 24 responder 36 27.8 2.82 (20.487 to 6.145)
ETN, etanercept; MTX, methotrexate; NP, non-progressor defined by TSS (0; TSS, total Sharp score.
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progressors were evaluated at week 52. Results are shown in
table 1. No statistically significant difference was observed in
the mean TSS or the percentage of non-progressors between the
12-week versus the 24-week responders in the etanercept or
etanercept plus methotrexate arms. In the methotrexate arm,
however, the 24-week responders showed a significant increase
in TSS at 52 weeks compared with the 12-week responders.
Predictors of improvement in response
No baseline characteristics or week 12 clinical variables (C-
reactive protein, erythrocyte sedimentation rate, swollen joint
count, tender joint count, Health Assessment Questionnaire,
visual analogue scale for pain, physician global assessment and
DAS28) were significantly associated with a delayed response at
24 weeks.
DISCUSSION
In this retrospective analysis, a substantial improvement in
clinical response was observed between 12 and 24 weeks in
subjects with rheumatoid arthritis in all three treatment arms
from the TEMPO trial, including those who were non or partial
responders at 12 weeks. The improvement in response at
24 weeks was most apparent in the etanercept plus methotrex-
ate arm, in which 37.5% of ACR20, 46.8% of ACR50 and 51.1%
of ACR70 non-responders became ACR20, ACR50 and ACR70
responders, respectively, at week 24. Similar improvements
were observed for DAS28 scores in all three treatment arms.
The delayed response observed at 24 weeks was largely
sustained in 80% of subjects to 52 weeks and was not associated
with an inferior outcome with regard to the inhibition of
radiographic progression at 52 weeks in the etanercept and
etanercept plus methotrexate arms.
There are no clear guidelines on the appropriate treatment
trial duration for TNF inhibitors. Recommendations from
international guidelines vary, with most indicating 12 weeks
as a time to assess response after TNF inhibitor therapy.
Whereas some recommend discontinuing therapy at 12 weeks
for non-responders, others allow for doctor’s discretion on
whether or not to continue therapy.
7–12
Importantly, an analysis of disease variables and patient
characteristics failed to identify any predictive factors.
The implications of this assessment are relevant with regard
to the subsequent treatment of patients ‘‘failing’’ TNF inhibitor
therapy at 12 weeks. It has been shown that patients who have
‘‘failed’’ therapy with a TNF inhibitor have somewhat lesser
ACR responses to any second-line biological therapy.
13–15
Therefore, optimising the first treatment course with a TNF
inhibitor could improve primary response rates and result in less
switching between biological agents.
Limitations of the current study include the retrospective
nature of the analysis. Moreover, these findings are from
patients enrolled in a randomised clinical trial who met the
specific inclusion criteria and had high disease activity.
Therefore, these observations may not reflect patients in a
real-world setting.
In conclusion, findings from this retrospective analysis
suggest that a significant proportion of patients who do not
achieve a clinical response 12 weeks after the initiation of
etanercept with or without methotrexate therapy may benefit
from continuing therapy for up to 24 weeks. Additional benefits
of continuing therapy for up to 24 weeks include the sustain-
ability of the 24-week gain in response through at least one year
while maintaining radiographic protection.
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Figure 2 Mean DAS28 scores in EULAR (moderate or good)
responders and non-responders.
DAS28, Disease Activity Score using 28 joints; ETN, etanercept; EULAR,
European League Against Rheumatism; MTX, methotrexate; N, total of
subgroup; NR, non-responder; R, responder.
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